<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article284</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/SPARCL" style="display:block; margin-bottom:10px;">SPARCL Original</a></li>
<h2><strong>SPARCL</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Atorvastatin for Stroke Prevention".The New England Journal of Medicine. 2006. 355(6):549-559. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with recent stroke or TIA and without known coronary heart disease, does atorvastatin reduce the risk of subsequent strokes or cardiovascular events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with recent stroke or TIA and without known coronary heart disease, daily treatment with 80 mg of atorvastatin reduced the overall incidence of strokes and major cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Randomized, double-blind, placebo-controlled trial.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria:<br/>
- Age &gt;18 years<br/>
- Stroke or TIA within one to six months of study entry<br/>
- LDL cholesterol levels 100-190 mg/dL<br/>
- No known coronary heart disease<br/>
<br/>
Exclusion Criteria:<br/>
- Atrial fibrillation, other cardiac sources of embolism, and subarachnoid hemorrhage<br/>
<br/>
Baseline Characteristics:<br/>
- Mean age: ~63 years<br/>
- 60% male<br/>
- Median LDL cholesterol: ~133 mg/dL<br/>
- Previous stroke: 66%<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Atorvastatin 80 mg per day versus placebo<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome:<br/>
- First nonfatal or fatal stroke<br/>
<br/>
Secondary Outcomes:<br/>
- Stroke or TIA<br/>
- Major coronary event<br/>
- Major cardiovascular event<br/>
- Acute coronary event<br/>
- Any coronary event<br/>
- Revascularization procedure<br/>
- Any cardiovascular event<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Increased risk of hemorrhagic stroke<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Pfizer.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
ClinicalTrials.gov number, NCT00147602
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
